NO975975L - Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav - Google Patents

Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav

Info

Publication number
NO975975L
NO975975L NO975975A NO975975A NO975975L NO 975975 L NO975975 L NO 975975L NO 975975 A NO975975 A NO 975975A NO 975975 A NO975975 A NO 975975A NO 975975 L NO975975 L NO 975975L
Authority
NO
Norway
Prior art keywords
preparation
receptor antagonists
vitronectin receptor
vitronectin
meanings
Prior art date
Application number
NO975975A
Other languages
English (en)
Norwegian (no)
Other versions
NO975975D0 (no
Inventor
Volkmar Wehner
Hans Ulrich Stilz
Anuschirwan Peyman
Karlheinz Scheunemann
Jean-Marie Ruxer
Denis Carniato
Jean-Michel Lefrancois
Thomas Richard Gadek
Robert Mcdowell
Original Assignee
Hoechst Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Genentech Inc filed Critical Hoechst Ag
Publication of NO975975D0 publication Critical patent/NO975975D0/no
Publication of NO975975L publication Critical patent/NO975975L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO975975A 1996-12-20 1997-12-19 Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav NO975975L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653645A DE19653645A1 (de) 1996-12-20 1996-12-20 Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung

Publications (2)

Publication Number Publication Date
NO975975D0 NO975975D0 (no) 1997-12-19
NO975975L true NO975975L (no) 1998-06-22

Family

ID=7815760

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975975A NO975975L (no) 1996-12-20 1997-12-19 Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav

Country Status (19)

Country Link
US (1) US5990145A (cs)
EP (1) EP0854145A3 (cs)
JP (1) JPH10182617A (cs)
KR (1) KR19980064419A (cs)
CN (1) CN1200373A (cs)
AR (1) AR010369A1 (cs)
AU (1) AU729760B2 (cs)
BR (1) BR9706386A (cs)
CA (1) CA2225267A1 (cs)
CZ (1) CZ411297A3 (cs)
DE (1) DE19653645A1 (cs)
HU (1) HUP9702509A3 (cs)
ID (1) ID19245A (cs)
IL (1) IL122643A0 (cs)
NO (1) NO975975L (cs)
NZ (1) NZ329429A (cs)
PL (1) PL323968A1 (cs)
TR (1) TR199701645A2 (cs)
ZA (1) ZA9711315B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
CN1398189A (zh) 1998-12-23 2003-02-19 G.D.西尔公司 用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
US6545032B1 (en) 1999-09-17 2003-04-08 Torrey Pines Institute For Molecular Studies Synthesis of [3,5,7]-H-imidazo[1,5-a] imidazol-2(3H)-one compounds
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
US7176199B2 (en) * 2001-03-19 2007-02-13 Dainippon Pharmaceutical Co., Ltd. Aryl-substituted alicyclic compound and medical composition comprising the same
ES2366775T3 (es) 2001-04-24 2011-10-25 Merck Patent Gmbh POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
ES2309209T3 (es) 2001-11-13 2008-12-16 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,4-benzodiazepinas sustituidas y uso de las mismas para el tratamiento del cancer.
US7205315B2 (en) * 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
BRPI0806596A2 (pt) 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
CN101686680B (zh) 2007-03-09 2015-12-09 伊沃泰克美国股份有限公司 作为p2x7调节剂的双环杂芳基化合物及其用途
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
EP2445534A2 (en) 2009-05-25 2012-05-02 Merck Patent GmbH Continuous administration of cilengitide in cancer treatments
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU666318B2 (en) * 1991-06-28 1996-02-08 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5204350A (en) * 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) * 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JP3322878B2 (ja) * 1992-10-14 2002-09-09 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
WO1994012181A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
SG63579A1 (en) * 1992-12-21 1999-03-30 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
CA2190870A1 (en) * 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
AU702661B2 (en) * 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
ES2197950T3 (es) * 1995-06-29 2004-01-16 Smithkline Beecham Corporation Antagonistas del receptor de la integrina.
CN1209060A (zh) * 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
JP2000502354A (ja) * 1995-12-29 2000-02-29 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
KR19990076877A (ko) * 1995-12-29 1999-10-25 스티븐 베네티아너 비트로넥틴 수용체 길항제
ES2171768T3 (es) * 1996-03-20 2002-09-16 Hoechst Ag Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten

Also Published As

Publication number Publication date
AU729760B2 (en) 2001-02-08
CA2225267A1 (en) 1998-06-20
NZ329429A (en) 1999-05-28
IL122643A0 (en) 1998-08-16
ZA9711315B (en) 1998-06-22
HU9702509D0 (en) 1998-03-02
BR9706386A (pt) 2003-04-22
CZ411297A3 (cs) 1998-07-15
HUP9702509A2 (hu) 1999-06-28
AU4846497A (en) 1998-06-25
KR19980064419A (ko) 1998-10-07
NO975975D0 (no) 1997-12-19
PL323968A1 (en) 1998-06-22
TR199701645A3 (tr) 1998-07-21
JPH10182617A (ja) 1998-07-07
TR199701645A2 (xx) 1998-07-21
MX9710389A (es) 1998-08-30
AR010369A1 (es) 2000-06-07
EP0854145A3 (de) 2000-03-22
US5990145A (en) 1999-11-23
CN1200373A (zh) 1998-12-02
EP0854145A2 (de) 1998-07-22
ID19245A (id) 1998-06-28
DE19653645A1 (de) 1998-06-25
HUP9702509A3 (en) 2001-04-28

Similar Documents

Publication Publication Date Title
NO983002L (no) Vitronectin-reseptor-antagonister
CA2211270A1 (en) Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
TR200000812T2 (tr) 2-metil-tieno- benzodiazepin formülasyonu.
NO992821L (no) Ketobenzamider som calpain-inhibitorer
AR006273A1 (es) Compuestos heterociclicos nitrogenados de anillos de 5 miembros como nuevos inhibidores de la resorcion osea y antagonistas de receptores de vitronectina,procedimiento para su preparacion, utilizacion de dichos compuestos para la preparacion de un medicamento, y preparado farmaceutico.
BG104544A (en) Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
NO20001514L (no) Vitronectin-reseptor-antagonist
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
NO990662L (no) Trombin-inhibitorer
TR199701645A2 (xx) Vitronektin resept�r antagonistleri,bunlar�n imalat� ve kullan�m�
IT1283232B1 (it) Procedimento per la sintesi di 2-buten-1, 4-diesteri
TR200100885T2 (tr) 2-Metil-tieno-benzodiazepin formülasyonu
TR200000786T2 (tr) Vitronektin reseptör antagonisti
DK0810991T3 (da) 1-Aryl-2-acylamino-ethan-forbindelser og deres anvendelse som neurokinin- især neurokinin-1-antagonister
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
NO990914L (no) Amorfe benzotiofener, fremgangsmÕter for fremstilling og fremgangsmÕter for anvendelse
ATE282417T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
WO2000007544A3 (en) Vitronectin receptor antagonists
NO20000518L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
NO944722L (no) 3-(fenylalkylaminoalkyloksy)-5-fenylpyrazol-forbindelser samt fremgangsmåter og mellomprodukter for deres fremstilling, og legemidler som inneholder disse forbindelsene
MY132635A (en) Cycloalkyl derivatives as inhibitors of bone resporption and vitronectin receptor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application